IN CASE YOU MISSED IT: This week, Techdirt published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), as a part of their series around Patent Quality Week. In his op-ed, Lane outlines the ways in which the pharmaceutical marketplace is impacted by Big Pharma’s manipulation and abuse of the U.S. patent system.  Specifically, […]

Continue Reading

IN CASE YOU MISSED IT: Today, STAT News published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), highlighting the crucial role that the next U.S. Patent and Trademark Office (USPTO) director will have on reducing drug costs for millions of American patients, many of which are already struggling financially due to […]

Continue Reading

IN CASE YOU MISSED IT: Today, Bloomberg Law published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), around the Federal Circuit’s recent decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. which undermines the ‘skinny label’ framework used by generic drug companies to describe their products as therapeutically equivalent to branded drugs.   In his op-ed, […]

Continue Reading

In case you missed it, please see the piece below in today’s Washington Post by two leading experts from Brigham and Women’s Hospital/Harvard Medical School that outlines how a Biden White House could take immediate steps address rising drug prices for patients and families by fixing our patent system….. Biden can lower drug prices without […]

Continue Reading

IN CASE YOU MISSED IT: This week, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around rising prescription drug prices and the need for reforms that can encourage competition and innovation to drive access and affordability.  In his op-ed, Lane highlights a recent national survey by the Campaign for Sustainable Rx Pricing, […]

Continue Reading

IN CASE YOU MISSED IT: This week, Axios reported that Humira, a medicine that treats a number of chronic conditions and is widely prescribed and used by millions of people around the world, reached $19.9 billion in global sales in 2018, marking an 8.2 percent increase from 2017.  While Humira is notably one of the most profitable […]

Continue Reading

WASHINGTON, DC: In case you missed it, STAT today highlighted a new analysis that shows AbbVie could have its patents on cancer drug Imbruvica extended through 2036, forcing consumers to spend an additional $41 billion for the cancer treatment drug.  As I-MAK details in a new report, this move would prevent cheaper generic alternatives from entering the market […]

Continue Reading

WASHINGTON, DC: In case you missed it, Politico today highlighted the significant drug pricing hikes made by big pharmaceutical companies as millions of patients struggle to access affordable drugs amidst the coronavirus pandemic.  This year alone, big Pharma companies conducted hundreds of new price increases on patients which would appear to confirm the fears of many Americans.  […]

Continue Reading

IN CASE YOU MISSED IT: This week, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around reforming the patent system to balance competition and innovation so that American patients have access to affordable drugs, especially as both the private and public sectors work to quickly discover a treatment for COVID-19.  […]

Continue Reading

IN CASE YOU MISSED IT: Recently, HealthAffairs highlighted a study by researchers at Brigham and Women’s Hospital and Harvard Medical School that showed the real effects of name-brand drug manufacturers maintaining their market exclusivity by preventing of generic competition from entering the marketplace.  Among 61 name-brand drugs at risk of losing their market exclusivity from 2010-2016, 45 […]

Continue Reading